Macquarie Group LTD Capricor Therapeutics, Inc. Transaction History
Macquarie Group LTD
- $87.4 Billion
- Q1 2024
A detailed history of Macquarie Group LTD transactions in Capricor Therapeutics, Inc. stock. As of the latest transaction made, Macquarie Group LTD holds 941 shares of CAPR stock, worth $4,488. This represents 0.0% of its overall portfolio holdings.
Number of Shares
941Holding current value
$4,488% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CAPR
# of Institutions
62Shares Held
4.74MCall Options Held
123KPut Options Held
53.8K-
Vanguard Group Inc Valley Forge, PA1.37MShares$6.52 Million0.0% of portfolio
-
Black Rock Inc. New York, NY382KShares$1.82 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA328KShares$1.57 Million0.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA316KShares$1.51 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny293KShares$1.4 Million0.0% of portfolio
About CAPRICOR THERAPEUTICS, INC.
- Ticker CAPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,346,200
- Market Cap $116M
- Description
- Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for th...